Morgan joined Forbion in 2025 as a Principal with a focus on our Growth Opportunities Fund building and managing the portfolio concentrating on late-stage life sciences companies.
Previously, Morgan was a Director of the Life Sciences Investment Banking Team at Van Lanschot Kempen. He was also a research analyst covering various publicly traded therapeutics companies at Point72, JP Morgan Chase, and Robert W. Baird. Morgan holds an M.Sc. in Accounting from the University of Virginia and a B.Sc. in Accounting from Lehigh University.
